Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 3239 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded172    
    Comments [Add]    

Recommend this journal

Year : 2005  |  Volume : 47  |  Issue : 2  |  Page : 84-88

Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients

1 Department of Psychiatry, Postgraduate Institute of Medical Education and Research Chandigarh, India
2 Department of Psychiatry Government Medical College and Hospital, Chandigarh, India

Correspondence Address:
Ajit Avasthi
Department of Psychiatry, Postgraduate Institute of Medical Education and Research Chandigarh 160012
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5545.55951

Rights and Permissions

Background: Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India. Aim: To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder. Methods: In this prospective study, patients (n=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Scale (MADRS). Results: Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile. Conclusion: Moclobemide is an effective antidepressant and is better tolerated than imipramine.



Print this article         Email this article